Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

V disease and is administered by intramuscular injection. The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose of Synagis should be administered prior to commencement of the RSV season, which usually starts in the fall and runs through the spring. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least one percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

The pivotal trial for Synagis was called the IMpact trial and comprised a total of 1,502 children who were randomized (500 placebo, 1,002 Synagis) in a double-blind, placebo-controlled protocol where 1,486 children completed the study's follow-up.

In the IMpact trial, monthly prophylaxis with Synagis via intramuscular injections was associated with a 55-percent reduction in hospitalization as a result of RSV (p=<0.001). Reductions were observed in both children with bronchopulmonary dysplasia (38 percent reduction) and premature children without BPD (78 percent reduction). Approximately 50 percent of the
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... Fla. and DUBLIN , ... ("we" or the "Company"), a biotechnology company pioneering the ... marketing of innovative therapies for cancer, HIV/AIDS, opportunistic infections ... to its shareholders from CEO Noreen Griffin The letter ... Inc. (the "Company" or "TNIB") received a number of ...
(Date:9/29/2014)... , Sept. 29, 2014  Moberg ( www.moberg.com ... CNS Monitor, a medical device used for advanced ... Mark certifies that a product has met European ... Europe . The CNS Monitor ... (EEG, or brain waves) to support neurological patient ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8Moberg CNS Monitor Receives European CE Mark Approval for Advanced Neurological Monitoring 2
... Annual Meeting- , , ... of a randomized phase III study presented at the ... The study in adult patients with hematological malignancies at ... demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid ...
... Analgesic Significantly Reduces Postop Pain, Opioid Use, and ... Standard Pain Medication , ... A Phase II dose escalation study of a ... who underwent total knee arthroplasty, or TKA, showed ...
Cached Medicine Technology:Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 2Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 3Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 4
(Date:9/30/2014)... Amy Norton HealthDay ... -- Long-acting contraceptive devices should be the first choice ... the American Academy of Pediatrics state. Although most ... two other forms of contraception -- intrauterine devices (IUDs) ... to the academy. And they should be the ...
(Date:9/30/2014)... VA (PRWEB) September 30, 2014 Visit ... of Chestnut Hill and you will find a loving ... together, Amyotrophic Lateral Sclerosis. , Steve was ... or Lou Gehrig’s Disease – just before the couple’s ... primary caregiver. , A new video, “Care, Support ...
(Date:9/30/2014)... Franklin, TN (PRWEB) September 30, 2014 ... millions of people throughout the United States and ... of Parkinson’s Disease are diagnosed each year, adding ... diagnosed with the disease. Approximately 400,000 people in ... 2.3 million worldwide. Add to these statistics the ...
(Date:9/30/2014)... 2014 Pivotal 5, LLC, a proven ... Life Time – The Healthy Way of Life CompanySM ... KettleWorX Group Training . KettleWorX Group Training is a ... offers consumers of all fitness levels a means to ... manner. The rollout to Life Time Athletic destinations will ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 (HealthDay ... the return of a common type of irregular heartbeat known ... percent of those taking fish oil for its omega-3 fatty ... of 16 months, compared to 63.2 percent of those ... the twin ills of inflammation or oxidative stress, which may ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 2Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 3Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3
... School of Medicine and colleagues discovered that the Notch ... types, and is also implicated in some cancers, is ... The findings appear this week in Cell Stem Cell, ... bone marrow stem cells. , Notch is one of ...
... the Head and Neck, NEW YORK, April 10 ... plastic and cosmetic surgery for the ethnic,patient, will speak ... day,Continuing Medical Education (CME) Accredited seminar entitled "Patient,Safety in ... 12 at the,University Club of New York., "Facial ...
... Support Event, ALEXANDRIA, Va., April 10 ... (NHDD), will be the largest,effort ever undertaken to ... "With healthcare, ,your decisions matter;, however, others ... Nathan A. Kottkamp, Chair, National,Healthcare Decisions Day. "All ...
... in wine that protect against dementia. This is shown in ... Sweden. , The findings are based on 1,458 women who ... 1968. When they were examined by physicians they were asked ... by selecting from seven categories on a scale from never ...
... - 7,000 deaths a year ... pharmacy error risk, - Half of consumers choose their pharmacies for ... ... One-third of America,s 225,million prescription-takers now report experiencing a prescription ...
... their children to a podiatrist,for foot ailments, BETHESDA, ... bring thousands of adults to doctors, offices every,day. But ... Medical Association (APMA) during April,s Foot Health Awareness,Month, many ... it comes to their children,s feet. In fact, only ...
Cached Medicine News:Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:Dr. Edmund Kwan to Speak on Facial Contouring Among Asian Patients at Cosmetic Surgery Seminar 2Health News:National Healthcare Decisions Day in All 50 States, DC, Puerto Rico, and Internationally 2Health News:Wine may protect against dementia 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 3Health News:Pediatric Survey Reveals Many Parents Neglect Their Children's Feet 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: